OTLK
vs
S&P 500
OTLK
S&P 500
Over the past 12 months, OTLK has significantly outperformed S&P 500, delivering a return of +42% compared to the S&P 500's +14% growth.
Stocks Performance
OTLK vs S&P 500
Performance Gap
OTLK vs S&P 500
Performance By Year
OTLK vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Outlook Therapeutics Inc
Glance View
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. The company is headquartered in Iselin, New Jersey and currently employs 9 full-time employees. The company went IPO on 2016-06-13. The firm focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. ONS-5010, is the Company's product candidate, which is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. Bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. Its clinical program for ONS-5010 in wet AMD involves three clinical trials, which includes NORSE ONE, NORSE TWO and NORSE THREE. Outlook sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets for the treatment of wet AMD, diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).
